EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study

Krystal Dinh iD, Shannon D Thomas iD, Tae Cho iD, John Swinnen iD, Phillip Crowe iD, Ramon L Varcoe iD

Vascular Specialist International · 31.12.2019 · 35 (4) · 225-231

DOI: 10.5758/vsi.2019.35.4.225 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular Specialist International, erschienen am 31.12.2019. Verfasst von Krystal Dinh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Prince of Wales Hospital, Australia. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We report short-term patency outcomes of a proof of concept study conducted to determine the efficacy of drug-eluting stent (DES) for the treatment of arteriovenous fistula (AVF) stenosis in hemodialysis patients. MATERIALS AND METHODS: This is a single-center, retrospective observational study involving 10 patients with AVF dysfunction treated with DESs between January 2017 and December 2017. The primary outcome was AVF patency confirmed by sonographic and clinical assessment at 1 month and 6 to 9 months after treatment. RESULTS: A total of 12 DESs were deployed in 10 patients with dysfunctional AVF (radiocephalic: 7, brachiocephalic: 3). During the early follow up (mean: 28.6 days), primary access circuit and DES patency was 100%, with an average volume flow rate of 886.4 mL/min. Nine patients were available for short-term follow up (mean: 202.4 days; 1 unrelated death), with a mean volume flow rate of 1,048.9 mL/min. The primary DES patency was 7/9 (77.8%), and 3 patients required angioplasty at other parts of the circuit (primary access circuit patency: 4/9 [44.4%]). The assisted primary access circuit patency was 77.8%. In 2 patients, the ultrasound revealed that the DESs were thrombosed without any antecedent stenosis; they were salvaged with angioplasty. Both patients previously underwent 2 DESs implanted and recently stopped dual antiplatelet therapy. B-mode sonographic assessment at all timepoints showed minimal intimal ingrowth on the stent struts. CONCLUSION: This study demonstrates acceptable short-term patency for DESs in the treatment of AVF stenosis. Dual antiplatelet therapy is probably mandatory in the short term.

Schlagwörter

Stichwörter der Autor:innen

Arteriovenous fistulaDrug-eluting stentsFistulaVascular access

Autor:innen und Institutionen

  • Department of Surgery, Prince of Wales Hospital, Australia.
  • Department of Vascular Surgery, Westmead Hospital, Australia.
  • Faculty of Medicine, University of New South Wales, Australia.
  • The Vascular Institute, Prince of Wales Hospital, Sydney, Australia.

ORCID-Profile: Krystal Dinh, Shannon D Thomas, Tae Cho, John Swinnen, Phillip Crowe, Ramon L Varcoe

Zitieren

APA

Dinh, K., Thomas, S. D., Cho, T., Swinnen, J., Crowe, P., & Varcoe, R. L. (2019). Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study. Vascular Specialist International, 35(4), 225-231. https://doi.org/10.5758/vsi.2019.35.4.225

Vancouver

Dinh K, Thomas SD, Cho T, Swinnen J, Crowe P, Varcoe RL. Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study. Vascular Specialist International. 2019;35(4):225-231. doi:10.5758/vsi.2019.35.4.225

BibTeX
@article{Dinh2019,
  author = {Dinh, Krystal and Thomas, Shannon D and Cho, Tae and Swinnen, John and Crowe, Phillip and Varcoe, Ramon L},
  title = {Use of Paclitaxel Eluting Stents in Arteriovenous Fistulas: A Pilot Study},
  journal = {Vascular Specialist International},
  year = {2019},
  volume = {35},
  number = {4},
  pages = {225--231},
  doi = {10.5758/vsi.2019.35.4.225}
}
Kostenlos starten →